Systems Pharmacology/PBPK Workshop with PK-Sim and MoBi at PAGE meeting
Physiologically based modeling of intrinsic and extrinsic factors influencing
pharmacokinetics
A Systems Pharmacology Workshop by Bayer using PK-Sim® and MoBi®
Monday, June 6th, Lisbon, Portugal
Modeling and simulation scientists in drug development are faced with ever
growing challenges regarding flexibility, accuracy and applicability of models
to support an increasing number of projects. Moreover, clinical programs can
benefit from more detailed mechanistic models as knowledge-driven drug
development is taken to the next level by dedicated software tools for
Quantitative Systems Pharmacology (QSP) applications. Such tools can provide a
valuable means for addressing these challenges in a flexible and versatile
manner and are supported by regulatory guidance such as the FDA Guidance for
industry - Drug-Drug Interaction studies.
In this one-day workshop, Bayer Technology Services (BTS) will focus on
teaching and demonstrating how to build fully integrated systems pharmacology
models using BTS' Software Suite with PK-Sim® and MoBi®, a QSP modeling &
simulation platform applicable for a wide number of use cases. These include
classic physiologically based pharmacokinetic (PBPK) approaches such as species
extrapolation, translating between (special) populations and drug-drug
interaction (DDI) prediction as well as more complex QSP models for different
indications.
Attendees will learn how to easily deal with challenging mechanistic modeling
tasks focusing on pharmacokinetics and pharmacodynamics, exemplified by several
real-life use cases. These will be introduced with in-depth lectures followed
by dedicated hands-on training sessions. Particular attention is given to
questions communicated by attendees, we will ensure that sufficient room will
be given for detailed and lively discussions.
Hands-on sessions will, among others, cover the following topics:
- how to develop and set-up PBPK models with PK-Sim®,
- how to scale an existing model to different populations (e.g. young,
elderly, renally impaired, or hepatically impaired populations)
- how to extend and couple models to investigate drug-drug interactions,
e.g. via a common transporter using MoBi®
- how automatic tracking and documentation functionalities available in
the software can be applied for better overview and transparency
We are looking forward to meeting you at the workshop and are happy to answer
questions regarding registration and organization:
[email protected]<mailto:[email protected]>
Additional information:
The workshop will be free of charge, the registration form is available at the
following link: http://www.systems-biology.com/index.php?id=2681
Best regards,
Donato Teutonico
Systems Pharmacology CV
[cid:C15DEDD5-288E-4312-857A-B6E1A5E2692F]
Bayer Technology Services GmbH
BTS-TD-ET-SPC, Systems Pharmacology CV
Building B106, 210
51368 Leverkusen, Germany
Tel: +49 214 30 55352
Mobile: +49 173 78 06651
E-mail: [email protected]
Web: http://www.bayer.com
Geschäftsführung: Armin Knors, Geschäftsführer
Vorsitzender des Aufsichtsrats: Hartmut Klusik
Sitz der Gesellschaft: Leverkusen | Amtsgericht Köln, HRB 49896